JP2024524933A5 - - Google Patents
Info
- Publication number
- JP2024524933A5 JP2024524933A5 JP2023577688A JP2023577688A JP2024524933A5 JP 2024524933 A5 JP2024524933 A5 JP 2024524933A5 JP 2023577688 A JP2023577688 A JP 2023577688A JP 2023577688 A JP2023577688 A JP 2023577688A JP 2024524933 A5 JP2024524933 A5 JP 2024524933A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- isomer
- hydrate
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110661394.5 | 2021-06-15 | ||
| CN202110661394 | 2021-06-15 | ||
| PCT/CN2022/099018 WO2022262784A1 (zh) | 2021-06-15 | 2022-06-15 | Idh突变体抑制剂及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024524933A JP2024524933A (ja) | 2024-07-09 |
| JP2024524933A5 true JP2024524933A5 (enExample) | 2025-06-23 |
| JP7884019B2 JP7884019B2 (ja) | 2026-07-02 |
Family
ID=84526875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577688A Active JP7884019B2 (ja) | 2021-06-15 | 2022-06-15 | Ｉｄｈ変異体阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240208978A1 (enExample) |
| EP (1) | EP4356914A4 (enExample) |
| JP (1) | JP7884019B2 (enExample) |
| KR (1) | KR20240021774A (enExample) |
| CN (1) | CN117460512A (enExample) |
| AU (1) | AU2022294860A1 (enExample) |
| BR (1) | BR112023024454A2 (enExample) |
| CA (1) | CA3217608A1 (enExample) |
| MX (1) | MX2023013664A (enExample) |
| WO (1) | WO2022262784A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026035776A1 (en) * | 2024-08-05 | 2026-02-12 | Frontier Medicines Corporation | Pi3k-alpha binding compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012184205A (ja) * | 2011-03-08 | 2012-09-27 | Dainippon Sumitomo Pharma Co Ltd | ２−アミノ置換８−オキソジヒドロプリン誘導体 |
| SMT202200255T1 (it) * | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| CA2903979A1 (en) * | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| MA46064B1 (fr) * | 2014-09-19 | 2020-04-30 | Forma Therapeutics Inc | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
| US9624175B2 (en) * | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2017019429A1 (en) | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
| JP6682043B2 (ja) | 2016-06-06 | 2020-04-15 | イーライ リリー アンド カンパニー | 変異体ｉｄｈ１阻害剤 |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| KR102232614B1 (ko) * | 2016-07-21 | 2021-03-29 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용 |
| JP6793836B2 (ja) * | 2016-12-16 | 2020-12-02 | イーライ リリー アンド カンパニー | 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物 |
| CN110872297B (zh) * | 2018-09-04 | 2023-02-14 | 上海再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| WO2020141439A1 (en) * | 2018-12-31 | 2020-07-09 | Integral Biosciences Private Limited | Heterocyclic compounds as mutant idh inhibitors |
-
2022
- 2022-06-15 BR BR112023024454A patent/BR112023024454A2/pt unknown
- 2022-06-15 MX MX2023013664A patent/MX2023013664A/es unknown
- 2022-06-15 WO PCT/CN2022/099018 patent/WO2022262784A1/zh not_active Ceased
- 2022-06-15 EP EP22824259.0A patent/EP4356914A4/en active Pending
- 2022-06-15 CN CN202280040684.0A patent/CN117460512A/zh active Pending
- 2022-06-15 US US18/287,885 patent/US20240208978A1/en active Pending
- 2022-06-15 KR KR1020237041032A patent/KR20240021774A/ko active Pending
- 2022-06-15 CA CA3217608A patent/CA3217608A1/en active Pending
- 2022-06-15 JP JP2023577688A patent/JP7884019B2/ja active Active
- 2022-06-15 AU AU2022294860A patent/AU2022294860A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516371A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2024071370A5 (enExample) | ||
| JP2021191784A5 (enExample) | ||
| JP2025013344A5 (enExample) | ||
| JP2023512175A5 (enExample) | ||
| ES2295009T3 (es) | Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar. | |
| JP2022191257A5 (enExample) | ||
| JP2022502500A5 (enExample) | ||
| JP2017528503A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2025161856A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| TW201247613A (en) | Ester derivatives of bimatoprost compositions and methods | |
| JP2021521118A5 (enExample) | ||
| JP2021167346A5 (enExample) | ||
| JP2021520400A (ja) | エダラボン医薬組成物 | |
| JP2013500977A5 (enExample) | ||
| JP2022538817A5 (enExample) | ||
| JP2019536812A5 (enExample) | ||
| JP2024541569A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| JP2022531251A5 (enExample) | ||
| JP2024516359A5 (enExample) | ||
| JP2025502064A5 (enExample) |